INT79598

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.60
First Reported 1998
Last Reported 2010
Negated 2
Speculated 3
Reported most in Abstract
Documents 16
Total Number 18
Disease Relevance 8.68
Pain Relevance 1.17

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (PDE5A) signal transduction (PDE5A) cellular_component (PDE5A)
Anatomy Link Frequency
corpus 2
penis 1
smooth muscle 1
body 1
PDE5A (Homo sapiens)
Pain Link Frequency Relevance Heat
alcohol 6 96.00 Very High Very High Very High
depression 6 95.32 Very High Very High Very High
Multiple sclerosis 8 94.36 High High
Central nervous system 15 91.92 High High
Glutamate 1 88.56 High High
headache 23 84.68 Quite High
ischemia 28 84.56 Quite High
Migraine 1 82.36 Quite High
adenocard 18 78.16 Quite High
sSRI 66 76.56 Quite High
Disease Link Frequency Relevance Heat
Reprotox - General 2 155 100.00 Very High Very High Very High
Erectile Dysfunction 74 99.76 Very High Very High Very High
Cardiovascular Disease 22 99.08 Very High Very High Very High
Pulmonary Hypertension 193 98.88 Very High Very High Very High
Premature Ejaculation 279 98.72 Very High Very High Very High
Diabetes Mellitus 49 98.72 Very High Very High Very High
Hypotension 25 98.40 Very High Very High Very High
Neurodegenerative Disease 21 98.32 Very High Very High Very High
Cognitive Disorder 8 97.08 Very High Very High Very High
Alcohol Addiction 3 96.24 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
However, PDE3 and PDE5 protein levels were unaffected by NO.
Neg (unaffected) Regulation (unaffected) of PDE5
1) Confidence 0.60 Published 2010 Journal Headache Section Body Doc Link 19751368 Disease Relevance 0 Pain Relevance 0
Long-term DETA NONOate administration induced an immediate mRNA up-regulation of PDE5A (1.9-fold, 0.5 hour), an early peak of PDE2A (1.4-fold, 1 and 2 hours) and later up-regulation of both PDE3B (1.6-fold, 4 hours) and PDE2A (1.7-fold, 8 hours and 1.2-fold after 24 hours).
Regulation (regulation) of PDE5A
2) Confidence 0.52 Published 2010 Journal Headache Section Body Doc Link 19751368 Disease Relevance 0 Pain Relevance 0
Sildenafil citrate, an oral therapy for erectile dysfunction, is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), the predominant isozyme metabolizing cGMP in the corpus cavernosum.
Regulation (metabolizing) of PDE5 in corpus associated with reprotox - general 2
3) Confidence 0.45 Published 1998 Journal Clin Ther Section Abstract Doc Link 9916601 Disease Relevance 0.17 Pain Relevance 0
Long-term treatment with PDE5i and excessive cGMP accumulation may up-regulate PDE5 (El-Galley et al 2001).
Spec (may) Regulation (regulate) of PDE5
4) Confidence 0.45 Published 2006 Journal Clinical Interventions in Aging Section Body Doc Link PMC2699643 Disease Relevance 0.22 Pain Relevance 0
Furthermore, the effects of two selective PDE5 inhibitors, sildenafil and UK-114,542, and a PDE1 inhibitor UK-90,234 on cGMP hydrolysis were investigated in human and guinea pig cerebral arteries.
Spec (investigated) Regulation (effects) of PDE5
5) Confidence 0.45 Published 2005 Journal Eur. J. Pharmacol. Section Abstract Doc Link 16182282 Disease Relevance 0.31 Pain Relevance 0.25
The PDE5 inhibitors are safe and effective in most patients with CVD, including those taking multiple antihypertensive drugs.
Regulation (effective) of PDE5 associated with cardiovascular disease
6) Confidence 0.45 Published 2004 Journal Clin Cardiol Section Abstract Doc Link 15115189 Disease Relevance 1.77 Pain Relevance 0.19
Patients should be advised that many treatment options are available for ED, including the phosphodiesterase type 5 (PDE5) inhibitors.
Regulation (available) of PDE5 associated with reprotox - general 2
7) Confidence 0.45 Published 2004 Journal Clin Cardiol Section Abstract Doc Link 15115189 Disease Relevance 1.67 Pain Relevance 0.19
The PDE5 inhibitors have no effect on the penis in the absence of sexual stimulation.
Neg (no) Regulation (effect) of PDE5 in penis
8) Confidence 0.44 Published 2004 Journal Clin Cardiol Section Abstract Doc Link 15115191 Disease Relevance 0.50 Pain Relevance 0.09
However, examination of the methodology of these studies, the adherence of methodology to the contemporary consensus of ideal clinical trial design[68] and the impact of study methodology on treatment outcomes, fails to provide any robust empirical evidence to support a role of PDE-5 inhibitors in the treatment of PE with the exception of men with PE and comorbid ED.
Regulation (role) of PDE-5 associated with reprotox - general 2 and premature ejaculation
9) Confidence 0.42 Published 2007 Journal Indian Journal of Urology : IJU : Journal of the Urological Society of India Section Body Doc Link PMC2721550 Disease Relevance 0.58 Pain Relevance 0.07
The relaxing effect of the phosphodiesterase type 5 (PDE5) inhibitors on vascular smooth muscle has attracted much attention, especially in persons with cardiovascular disease.
Regulation (effect) of PDE5 in smooth muscle associated with cardiovascular disease
10) Confidence 0.41 Published 2004 Journal Clin Cardiol Section Abstract Doc Link 15115192 Disease Relevance 0.29 Pain Relevance 0.06
Sildenafil citrate, an oral therapy for erectile dysfunction, is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), the predominant isozyme metabolizing cGMP in the corpus cavernosum.
Regulation (metabolizing) of phosphodiesterase type 5 in corpus associated with reprotox - general 2
11) Confidence 0.39 Published 1998 Journal Clin Ther Section Abstract Doc Link 9916601 Disease Relevance 0.17 Pain Relevance 0
The potential role of different PDE5A promoters in the effect of PDE5 inhibitors is currently being investigated (Lin 2004).
Regulation (effect) of PDE5
12) Confidence 0.37 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2518390 Disease Relevance 0 Pain Relevance 0
It is interesting to speculate on PDE-5 inhibitor action in this part of the body.
Regulation (speculate) of PDE-5 in body
13) Confidence 0.28 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936309 Disease Relevance 0.05 Pain Relevance 0.07
Several lines of evidence indicate that targeting PDE5 with sildenafil offers novel strategies in the treatment of age-related memory impairment.
Regulation (targeting) of PDE5 associated with cognitive disorder
14) Confidence 0.27 Published 2007 Journal Pharmacol Rep Section Abstract Doc Link 17556793 Disease Relevance 0.75 Pain Relevance 0.25
PDE5Is have also been associated with sudden sensorineural hearing loss,61 and studies of audiometric properties in men and experimental animals using sildenafil or vardenafil have suggested changes in hearing.62,63 Although we are not aware of any published studies directly linking tadalafil to hearing changes, the possibility of a PDE5I class effect on hearing must be considered and taken seriously by patients and providers.


Spec (possibility) Regulation (effect) of PDE5I associated with sensorineural hearing loss
15) Confidence 0.25 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2939761 Disease Relevance 0.26 Pain Relevance 0
We aimed to evaluate the effects of the phosphodiesterase 5 inhibitor sildenafil on CFR in diabetics with erectile dysfunction.


Regulation (effects) of phosphodiesterase 5 associated with reprotox - general 2 and diabetes mellitus
16) Confidence 0.10 Published 2003 Journal Cardiovasc Diabetol Section Abstract Doc Link PMC194431 Disease Relevance 1.01 Pain Relevance 0
Allosteric binding of cGMP to PDE5 regulatory domain increases affinity of the catalytic site for cGMP, thereby stimulating the rate of cGMP hydrolysis (Thomas et al 1990b; Mullershausen et al 2001; Okada and Asakawa 2002; Corbin et al 2003; Rybalkin et al 2003). cGMP binding to the regulatory domain also stimulates phosphorylation of PDE5 by cGMP-dependent protein kinase (Thomas et al 1990b; Wyatt et al 1998; Mullershausen et al 2001; Murthy 2001; Rybalkin et al 2002b). cGMP binding to these sites must be preceded by occupation of the catalytic site by cGMP (Francis et al 1980; Thomas et al 1990b) and it appears that cGMP binding to the regulatory domain produces a conformational change in PDE5 that exposes Ser-92 allowing phosphorylation which increases affinity of the regulatory domain for cGMP and increases catalytic activity as well (Corbin et al 2000).
Regulation (change) of PDE5
17) Confidence 0.05 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2650605 Disease Relevance 0 Pain Relevance 0
Two other specific phosphodiesterase-5 inhibitors: zapri-nars and dipyridamole seem to be potentially very effective in the management of acute pulmonary hypertension.
Regulation (effective) of phosphodiesterase-5 associated with pulmonary hypertension
18) Confidence 0.04 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2605326 Disease Relevance 0.92 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox